Biocon Limited

Biocon India Limited

Bicon Limited

Joy Mathew

Madhavan Sridharan

Ganesh Sambasivam

Sambasivam Ganesh

Poornaprajna Acharya

Tom Thomas Puthiaparampil

Acharya Poornaprajna

Ravindra Chandrappa

Padudevastana Sathya Shanker

Sumitra Srinath

Sandhya Ujire

In one aspect, the invention provides a process for the production of 5-(4-Fluoro-phenyl)-2-isopropyl-4-phenyl-1-(3,5,7-trihydroxy-heptyl)-1H-pyrrole-3-carboxylic acid phenylamide hemicalcium salt, stereoisomers thereof or polymorphs thereof from a (6-{2-[2-(4-Fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrolidin-1-yl]-ethyl}-2-phenyl-[1,3,2]dioxaborinan-4-yl)-acetic acid tert-butyl ester.

Process for the production of atorvastatin calcium

In one aspect, the invention provides a process for the preparation of an amorphous HMG-CoA reductase inhibitor and hydrates thereof of desired particle size, which comprises: dissolving the HMG-CoA reductase inhibitor in a hydroxylic solvent, and removing the solvent by freeze-drying.

Amorphous HMG-CoA reductase inhibitors of desired particle size

In one aspect, the invention provides a process for the preparation of a compound of Formula I  wherein G is alkyl or aryl, by employing a novel halo-substituted active methylene compound of Formula III  wherein X is halogen, and process of preparation thereof.

Halo-substituted active methylene compounds

The present invention discusses a novel process for the synthesis of [R-(R*,R*)]-2-(4-fluorophenyl)-B,D-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium, atorvastatin. The compound so prepared is useful as inhibitor of the HMG-CoA reductase and may thus be used as hypolipidemic and hypocholesterolemic agent.

Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds

Process for manufacturing Simvastatin and novel intermediates thereof

Process for manufacturing simvastatin and novel intermediates thereof

This invention describes the synthesis of simvastatin from lovastatin by converting the lovastatin to lova amide using a secondary amine and subsequent reaction with a metal amide base generated from n-butyl lithium and pyrrolidine and followed by treatment with methyl iodide to give desired C-methylated intermediate. This intermediate was further transformed to the final product, simvastatin. This method of production consumes lesser quantities of metal amide, gives fewer side reactions and a lowered overall cost of manufacture of simvastatin than other procedures reported.

Process for manufacturing simvastatin and the novel intermediates

Growing community of inventors

Karnataka, India

Joy Mathew